Add BrightSurf on Google Email

Scientists uncover how vaccine adjuvants separate protection from reactogenicity

Researchers found that squalene-based adjuvants activate distinct pathways for vaccine protection and reactogenicity, including the role of IL-1β in enhancing efficacy and IL-1α in triggering local swelling. The study's findings could lead to safer vaccine design by targeting specific immune mechanisms.

SourceThe Institute of Medical Science, The University of Tokyo·Journalnpj Vaccines·TypeExperimental study·DateApr 13, 2026

A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior

Researchers investigated how two CAR T cells kill cancer with distinct signaling domains. CD28.ζ-CAR molecules work quickly and efficiently, while 4-1BB.ζ-CAR molecules linger in lipid rafts for sustained collaborative killing of tumor cells. This study aims to design CAR molecules maximizing antitumor activity beyond B cell malignancies.

SourceBaylor College of Medicine·JournalScience Advances·DateJan 10, 2025

St. Jude scientists create more efficient CAR immunotherapies using a molecular anchor

Scientists at St. Jude Children's Research Hospital developed a new design for chimeric antigen receptors (CARs) by adding a molecular anchor, increasing the anti-cancer activity of cellular immunotherapies in cancer models. The anchored CARs improved cancer killing and survival rates in animal models of multiple tumor types.

SourceSt. Jude Children's Research Hospital·JournalNature Biotechnology·TypeExperimental study·DateFeb 2, 2023

T cells use force to destroy cancer cells

Researchers at UNSW Sydney discovered that T cells use mechanical forces to propel lytic granules towards cancer cell membranes. The study found that the shape of the target membrane plays a crucial role in T cell-mediated cancer cell killing, with a bias towards outwardly curved membranes.

SourceUniversity of New South Wales·JournalDevelopmental Cell·TypeExperimental study·DateSep 15, 2022

La Jolla Institute discovers previously unknown cell interaction key in immune system attacks

Researchers at La Jolla Institute have identified a previously unknown molecular interaction between protein kinase C theta and CD28 that is essential for T lymphocyte activation. This discovery opens up a novel therapeutic avenue for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis by blocking the cellular inter...

SourceLa Jolla Institute for Immunology·JournalNature Immunology·DateOct 2, 2011